Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mBTCvax
- Development stage
- Phase 1
- Lead developer
- Johns Hopkins University
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
**mBTCvax** is an investigational, personalized peptide-based therapeutic cancer vaccine for biliary tract cancers. Each patient-specific vaccine contains selected mutated tumor peptide neoantigens from an oncogenic driver alteration plus the immune adjuvant polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose, also known as poly-ICLC or Hiltonol. The vaccine is intended to induce neoantigen-specific cytotoxic T-lymphocyte responses against tumor cells expressing the selected mutations; poly-ICLC activates innate immune signaling through Toll-like receptor 3 to enhance vaccine immunogenicity. It is being evaluated by Johns Hopkins in a Phase 1 study with durvalumab and tremelimumab for advanced biliary tract cancer.
- Other names
- mBTC vaxpersonalized peptide cancer vaccine mBTCvax
02
Targets
TCR (T cell antigen receptor complex)TSNA (Patient-specific mutant tumor neoantigen)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on mBTCvax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mBTCvax.